Chinese company to invest $150 million in biologics manufacturing

| By | China, Drug Manufacturing, R&D

Changzhou Qianhong Bio-pharma started construction of the phase two of pharmaceuticals production facility at Changzhou National Hi-Tech District (China) on November 28.

After expanding the facility Chinese manufacturer will add 200 million tablets and 60 million injections to production as well as manufacturing of molecular diagnosis reagents. The company will invest nearly $150 million into R&D and manufacturing of innovative biologics.

Changzhou Qianhong Bio-pharma, a leading biochemical maker of polysaccharides and enzymes drugs, is a major manufacturer of pancreatic kininogenase, heparin sodium and low molecular weight heparin, as well as compound digestive enzyme preparations and asparaginase, all of which had never been produced in China.

SOURCE: prnewswire
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.